论文部分内容阅读
研究显示白细胞介素2（IL-2）在人类免疫缺陷症病毒（HIV）感染病人的治疗中比其他抗病毒药物如叠氮胸苷（AZT）更加有效,尤其是在免疫系统仍发挥作用的病人中。 CD_4细胞是HIV侵犯的靶细胞,CD_4细胞进行性减少是艾滋病发病的标志。美国国立变态反应和传染病研究所（NIAID）Lane等研究显示用IL-2增高CD_4计数的持续时间可超过两年以上,远比用AZT治疗的作用时间长。对25例病人每两个月静脉输注5天IL-2进行治疗,日剂量如600万～1800万IU。结果显示,在10例CD_4计数≥200/mm~3的病人中,IL-2的治疗有很大效果。其中6例病人在治疗1年后CD_4计数增高50％,1例在治疗12个月后CD_4计数从554/mm~3上升到 1998/mm~3,其余4例CD_4计数稳定或稍有
Studies have shown that interleukin 2 (IL-2) is more effective than other antiviral drugs such as AZT in the treatment of patients with human immunodeficiency virus (HIV) infection, especially in the immune system In the patient. CD_4 cells are HIV target cells, CD_4 cells progressively reduce the incidence of AIDS is a sign. Studies by the National Institute of Allergy and Infectious Diseases (NIAID) Lane et al. Showed that the duration of CD_4 counting with IL-2 increased more than two years, far longer than treatment with AZT. Twenty-five patients received intravenous infusion of IL-2 every two months for treatment at a daily dose of 6 million to 18 million IU. The results showed that in 10 cases of CD_4 count ≥ 200 / mm ~ 3 of patients, the treatment of IL-2 has a great effect. Among them, 6 patients increased CD_4 count by 50% at 1 year after treatment, CD4 count increased from 554 / mm ~ 3 to 1998 / mm ~ 3 in 1 patient after 12 months of treatment, and the remaining 4 patients had stable or slight CD_4 count